<?xml version="1.0" encoding="UTF-8"?>
<!--
  ONQ-DRUG-002: Bevacizumab Indications
  TUSS: 40501327
  Versao: 3.1.0-LEAN-TIER2 (2026-02-08)
  Especialidade: Oncologia

  ============================================================================
  INDICACOES APROVADAS (FDA/ANVISA):
  ============================================================================
  - CCR metastatico: 1L + quimio (IFL, FOLFOX, FOLFIRI)
  - CPNPC nao-escamoso: 1L + carbo/paclitaxel
  - CCR: 1L ou 2L (em sequencia apos progressao)
  - Glioblastoma recorrente: monoterapia
  - RCC: + interferon (historico, menos usado)

  ============================================================================
  INDICACOES NAO RECOMENDADAS:
  ============================================================================
  - Cancer de mama metastatico (RIBBON-1/AVADO: sem beneficio OS)
  - CPNPC escamoso (risco de hemoptise fatal)
  - Cirurgia recente (<28 dias)

  ============================================================================
  DOCUMENTACAO OBRIGATORIA:
  ============================================================================
  - Tipo histologico confirmado
  - Linha de tratamento
  - Contraindicacoes verificadas (HAS nao controlada, proteinuria, hemorragia)

  ============================================================================
  REFERENCIAS NORMATIVAS:
  ============================================================================
  - AVF2107g Trial (Hurwitz NEJM 2004) - CRC
  - ECOG 4599 - NSCLC
  - FDA Label Bevacizumab
  - NCCN CRC/NSCLC/RCC Guidelines
-->
<definitions xmlns="https://www.omg.org/spec/DMN/20191111/MODEL/" xmlns:dmndi="https://www.omg.org/spec/DMN/20191111/DMNDI/" xmlns:dc="http://www.omg.org/spec/DMN/20180521/DC/" xmlns:modeler="http://camunda.org/schema/modeler/1.0" id="Definitions_ONQ_DRUG_002" name="DRD" namespace="http://camunda.org/schema/1.0/dmn" exporter="Camunda Modeler" exporterVersion="5.14.0" modeler:executionPlatform="Camunda Cloud" modeler:executionPlatformVersion="8.2.0">
  <decision id="Decision_ONQ_DRUG_002" name="ONQ-DRUG-002: Bevacizumab Indications [LEAN TIER-2]">
    <decisionTable id="DecisionTable_ONQ_DRUG_002" hitPolicy="FIRST">
      <input id="Input_tumor_type" label="Tumor Type">
        <inputExpression id="InputExpression_tumor_type" typeRef="string">
          <text>tumorType</text>
        </inputExpression>
      </input>
      <input id="Input_line" label="Treatment Line">
        <inputExpression id="InputExpression_line" typeRef="number">
          <text>treatmentLine</text>
        </inputExpression>
      </input>
      <input id="Input_histology" label="Histology">
        <inputExpression id="InputExpression_histology" typeRef="string">
          <text>histology</text>
        </inputExpression>
      </input>
      <input id="Input_contraindications" label="Contraindications Present">
        <inputExpression id="InputExpression_contraindications" typeRef="boolean">
          <text>contraindicationsPresent</text>
        </inputExpression>
      </input>
      <input id="Input_ultimoProcedimentoDias" label="Dias Desde Ultimo Procedimento">
        <inputExpression id="InputExpression_ultimoProcedimentoDias" typeRef="number">
          <text>ultimoProcedimentoDias</text>
        </inputExpression>
      </input>
      <output id="Output_resultado" label="Resultado" name="resultado" typeRef="string">
        <outputValues id="UnaryTests_resultado">
          <text>"Aprovado","Reprovado","Pendente"</text>
        </outputValues>
      </output>
      <output id="Output_observacao" label="Observacao" name="observacao" typeRef="string" />
      <output id="Output_fundamentacao" label="Fundamentacao" name="fundamentacao" typeRef="string" />
      <!-- Output 4: Alertas de Desperdicio - Anti-Waste Intelligence -->
      <output id="Output_alertasDesperdicio" label="Alertas de Desperdicio" name="alertasDesperdicio" typeRef="string">
        <outputValues id="OutputValues_alertasDesperdicio">
          <text>"NENHUM","DUP","FREQ","ESC","DOC","PROT","MULTI"</text>
        </outputValues>
      </output>
      <!-- Output 5: Acao Recomendada -->
      <output id="Output_acaoRecomendada" label="Acao Recomendada" name="acaoRecomendada" typeRef="string">
        <outputValues id="OutputValues_acaoRecomendada">
          <text>"APROVAR","NEGAR","SOLICITAR_INFO","AGUARDAR_PRAZO","SUGERIR_ALTERNATIVA"</text>
        </outputValues>
      </output>
      <!-- WASTE DETECTION: DUP - Dose duplicada antes do intervalo minimo -->
      <rule id="Rule_40501327_DUP_dose">
        <description>DUP - Dose repetida antes do intervalo minimo de 14 dias</description>
        <inputEntry id="InputEntry_tumor_type_dup">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_dup">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_dup">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_dup">
          <text>-</text>
        </inputEntry>
        <inputEntry id="IE_Rule_40501327_DUP_dose_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_dup">
          <text>"Reprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_dup">
          <text>"Dose repetida em menos de 14 dias. Intervalo minimo entre doses de bevacizumabe (infusional) nao respeitado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_dup">
          <text>"NCCN 2024: Bevacizumabe infusional intervalo minimo 14 dias conforme protocolo. Dose prematura sem beneficio adicional"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_dup_alertasDesperdicio">
          <text>"DUP"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_dup_acaoRecomendada">
          <text>"AGUARDAR_PRAZO"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_reject_contraindicated">
        <description>Reject if contraindications present</description>
        <inputEntry id="InputEntry_tumor_type_contra">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_contra">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_contra">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_contra">
          <text>true</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_reject_contraindicated_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_contra">
          <text>"Reprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_contra">
          <text>"Bevacizumabe contraindicado: verificar HAS, proteinuria, hemorragia, cirurgia recente"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_contra">
          <text>"Contraindicacoes absolutas: cirurgia &lt;28 dias, HAS nao controlada, perfuracao GI previa"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_contraindicated_alertasDesperdicio">
          <text>"PROT"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_contraindicated_acaoRecomendada">
          <text>"NEGAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_reject_breast">
        <description>Reject bevacizumab for breast cancer</description>
        <inputEntry id="InputEntry_tumor_type_breast">
          <text>"breast"</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_breast">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_breast">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_breast">
          <text>-</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_reject_breast_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_breast">
          <text>"Reprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_breast">
          <text>"Bevacizumabe NAO indicado para cancer de mama: sem beneficio em sobrevida"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_breast">
          <text>"RIBBON-1/AVADO: sem beneficio OS em mama; FDA revogou indicacao em 2011"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_breast_alertasDesperdicio">
          <text>"PROT"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_breast_acaoRecomendada">
          <text>"NEGAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_reject_squamous_nsclc">
        <description>Reject for squamous cell NSCLC</description>
        <inputEntry id="InputEntry_tumor_type_squam">
          <text>"lung_cancer","NSCLC"</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_squam">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_squam">
          <text>"squamous"</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_squam">
          <text>-</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_reject_squamous_nsclc_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_squam">
          <text>"Reprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_squam">
          <text>"Bevacizumabe contraindicado em CPNPC escamoso: risco de hemoptise fatal"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_squam">
          <text>"ECOG 4599: hemoptise fatal em 31% escamoso central; excluido de estudos subsequentes"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_squamous_nsclc_alertasDesperdicio">
          <text>"PROT"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_reject_squamous_nsclc_acaoRecomendada">
          <text>"NEGAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_approve_crc">
        <description>Approve for metastatic CRC 1L or 2L</description>
        <inputEntry id="InputEntry_tumor_type_crc">
          <text>"colorectal","colon","rectal"</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_crc">
          <text>[1..2]</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_crc">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_crc">
          <text>false</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_approve_crc_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_crc">
          <text>"Aprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_crc">
          <text>"Bevacizumabe aprovado para CCRm 1L/2L + FOLFOX/FOLFIRI"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_crc">
          <text>"AVF2107g: OS 20.3 vs 15.6 meses com beva+IFL; continuar alem progressao em TML beneficia"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_crc_alertasDesperdicio">
          <text>"NENHUM"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_crc_acaoRecomendada">
          <text>"APROVAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_approve_nsclc_nonsquam">
        <description>Approve for non-squamous NSCLC 1L</description>
        <inputEntry id="InputEntry_tumor_type_nsclc">
          <text>"lung_cancer","NSCLC"</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_nsclc">
          <text>1</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_nsclc">
          <text>"adenocarcinoma","non_squamous"</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_nsclc">
          <text>false</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_approve_nsclc_nonsquam_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_nsclc">
          <text>"Aprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_nsclc">
          <text>"Bevacizumabe aprovado para CPNPC nao-escamoso 1L + carbo/paclitaxel"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_nsclc">
          <text>"ECOG 4599: OS 12.3 vs 10.3 meses com beva+carbo/pacli; beneficio em adenocarcinoma"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_nsclc_nonsquam_alertasDesperdicio">
          <text>"NENHUM"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_nsclc_nonsquam_acaoRecomendada">
          <text>"APROVAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_approve_gbm">
        <description>Approve for recurrent glioblastoma</description>
        <inputEntry id="InputEntry_tumor_type_gbm">
          <text>"glioblastoma","GBM"</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_gbm">
          <text>&gt;= 2</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_gbm">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_gbm">
          <text>false</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_approve_gbm_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_gbm">
          <text>"Aprovado"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_gbm">
          <text>"Bevacizumabe aprovado para GBM recorrente: monoterapia ou + lomustina"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_gbm">
          <text>"BRAIN/AVF3708g: ORR 28-38% em GBM recorrente; reducao de edema e corticoide"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_gbm_alertasDesperdicio">
          <text>"NENHUM"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_approve_gbm_acaoRecomendada">
          <text>"APROVAR"</text>
        </outputEntry>
      </rule>
      <rule id="DecisionRule_fallback">
        <description>Fallback rule for incomplete data</description>
        <inputEntry id="InputEntry_tumor_type_fallback">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_line_fallback">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_histology_fallback">
          <text>-</text>
        </inputEntry>
        <inputEntry id="InputEntry_contraindications_fallback">
          <text>-</text>
        </inputEntry>
        <inputEntry id="IE_DecisionRule_fallback_ultimo"><text>-</text></inputEntry>
        <outputEntry id="OutputEntry_resultado_fallback">
          <text>"Pendente"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_observacao_fallback">
          <text>"Dados insuficientes para avaliacao de bevacizumabe"</text>
        </outputEntry>
        <outputEntry id="OutputEntry_fundamentacao_fallback">
          <text>"Necessario: tipo tumoral, linha, histologia, contraindicacoes"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_fallback_alertasDesperdicio">
          <text>"NENHUM"</text>
        </outputEntry>
        <outputEntry id="OE_DecisionRule_fallback_acaoRecomendada">
          <text>"SOLICITAR_INFO"</text>
        </outputEntry>
      </rule>
    </decisionTable>
  </decision>
  <dmndi:DMNDI>
    <dmndi:DMNDiagram>
      <dmndi:DMNShape dmnElementRef="Decision_ONQ_DRUG_002">
        <dc:Bounds height="80" width="180" x="160" y="100" />
      </dmndi:DMNShape>
    </dmndi:DMNDiagram>
  </dmndi:DMNDI>
</definitions>
